Duchenne/Becker and limb-girdle muscular dystrophies share clinical symptoms like muscle weakness and wasting but differ in clinical presentation and severity. To get a closer view on the differentiating molecular events responsible for the muscular dystrophies, we have carried out a comparative gene expression profiling of hindlimb muscles of the following mouse models: dystrophin-deficient (mdx, mdx 3cv ), sarcoglycan-deficient (Sgca null, Sgcb null, Sgcg null, Sgcd null), dysferlin-deficient (Dysf null, SJL Dysf ), sarcospan-deficient (Sspn null), and wild-type (C57Bl/6, C57Bl/10) mice. The expression profiles clearly discriminated between severely affected (dystrophinopathies and sarcoglycanopathies) and mildly or nonaffected models (dysferlinopathies, sarcospan-deficiency, wild-type). Dystrophin-deficient and sarcoglycandeficient profiles were remarkably similar, sharing inflammatory and structural remodeling processes. These processes were also ongoing in dysferlin-deficient animals, albeit at lower levels, in agreement with the later age of onset of this muscular dystrophy. The inflammatory proteins Spp1 and S100a9 were up-regulated in all models, including sarcospan-deficient mice, which points, for the first time, at a subtle phenotype for Sspn null mice. In conclusion, we identified biomarker genes for which expression correlates with the severity of the disease, which can be used for monitoring disease progression. This comparative study is an integrating step toward the development of an expression profiling-based diagnostic approach for muscular dystrophies in humans. of muscular dystrophies is caused by mutations in genes coding for constituents of the dystrophin-associated glycoprotein complex (DGC). The DGC is a multimeric protein complex composed of integral, peripheral, and cytoplasmic proteins expressed at the sarcolemma of muscle fibers. One likely role of the DGC is to maintain the sarcolemma stability by providing a physical link between the extracellular matrix and the actin cytoskeleton. This link occurs through the trio dystrophin-dystroglycan-laminin-2. Dystrophin binds to cytoskeletal F-actin and the transmembrane β-subunit of dystroglycan. Dystroglycan binds to laminin-2 in the extracellular matrix via its α-subunit (3). The trio dystrophin-dystroglycan-laminin-2 is stabilized by other DGC components such as the sarcoglycan-sarcospan complex (SGC), which resides in the sarcolemma. In skeletal muscle, the SGC contains four glycosylated subunits (α-, β-, γ-, and δ-sarcoglycan) and sarcospan (4).
Human muscle biopsies display large inter-individual variation in gene expression due to differences in genetic make-up, age, and exposure to environmental factors, necessitating the evaluation of large patient groups. To facilitate the delineation of the molecular mechanisms underlying the phenotypic characteristics, we decided to perform large-scale gene expression profiling of mouse models known to recapitulate different human muscular dystrophies (Fig. 1) . Mice with early onset/severe phenotypes, represented by dystrophinopathies (mdx and mdx 3cv ) and sarcoglycanopathies (Sgca null, Sgcb null, Sgcg null and Sgcd null), and late onset/mild phenotypes, represented by dysferlinopathies (SJL Dysf and Dysf null), were included in the study (Table 1) . Sarcospan-deficient (Sspn null) mice, with no apparent muscular phenotype, were also included. Two wild-type strains (C57Bl/6 and C57Bl/10) served as controls. Although these mouse models have been extensively studied on phenotypic characteristics, like severity, age of onset, loss of the DGC, lifespan, and the temporal manifestation of the pathology (reviewed in ref 24), a large-scale comparison of gene expression patterns has not yet been performed. As a starting point, and to avoid age-dependent differences in gene expression, we evaluated young adult male mice (8 wk of age). At this age, mdx mice show most prominent changes in gene expression compared with wild-type (25) and sarcoglycan-deficient animals are severely dystrophic. On the contrary, the dysferlin-deficient mice are only mildly affected at this age (11, 26) . Our data demonstrate that gene expression patterns classify the animals according to the severity of the disease and point at common secondary disease mechanisms.
MATERIALS AND METHODS

Target preparation and hybridization
Hindlimb muscle tissue (m. quadriceps femoris) was isolated from the following mice at the age of 8 wk (2 individuals per strain): mdx (mdx) (C57Bl/10ScSn-mdx/J, The Jackson Laboratory x C57Bl/6NCrl, Charles River x CBA/JCrl, Charles River), mdx 3cv (mdx 3cv ) (27), Sgca null (Sgca−/−) (28), Sgcb null (Sgcb−/−) (29), Sgcb null-2 (Sgcb−/−2) (30), Sgcg null (Sgcg−/−) (31), Sgcd null (Sgcd−/−) (32), Dysf null (Dysf−/−) (11) , SJL (SJL Dysf ) (SJL/J, The Jackson Laboratory), Sspn null (Sspn−/−) (33), C57Bl/10 (Bl10) (C57Bl/10ScSnOlaHsd, Harland), C57Bl/6 (Bl6) (C57Bl/6JOlaHsd, Harland), and hDMD mice, which contain the full-length 2.3 Mb human dystrophin gene (hDMD, 't Hoen et al., unpublished observations). Expression profiles of the hDMD mice will be discussed in a separate manuscript. The expression profiles of the Sgcb null-2 mice were not included in the analysis, for reasons indicated in the Discussion. Total RNA was isolated as described previously (34). cRNA was prepared by linear amplification and concurrent incorporation of amino-allyl UTP, followed by chemical coupling to monoreactive Cy3 or Cy5 dyes (35). Labeled targets (1.5 µg cRNA per target) were hybridized overnight on prehybridized murine oligonucleotide microarrays (65-mer with 5′-hexylaminolinker, Sigma-Genosys mouse 7.5 K oligonucleotide library, printed in duplicate) using an automatic hybridization station (GeneTac, Genomic Solutions, Ann Arbor, MI). Posthybridization washes were performed as described previously (35).
Data analysis
Hybridizations were performed in a dye-swap fashion using a randomized design, while avoiding co-hybridization of samples from the same model (Supplemental Table 1 ). This experimental design generates eight data points per gene per mouse model (2 biological replicates with 4 technical replicates each). The randomized experimental design facilitates an intensity-based analysis procedure, since ratio-based analysis procedures become complicated and inefficient in multi-class comparisons (36). Spot intensities were evaluated with feature extraction software (GenePix Pro 5, Axon, Union City, CA). Local background corrected, median spot intensities were normalized simultaneously for all microarray experiments using variance stabilization and normalization (VSN) as described previously (37). This transformation coincides with the natural logarithm for the high intensities. Two filtering criteria were applied. First, genes that were flagged in at least four out of eight observations for a particular genotype were excluded to minimize the influence of unreliable spots (specks, high background). Since samples were randomly hybridized with each other, and spots were flagged only when signals in both channels were below background, it is very unlikely that genes that are expressed only in one or a few models were excluded from the analysis. Second, 88 genes previously shown to demonstrate variation in expression in the muscle due to differences in the genetic background (34) were excluded from the analysis. In the end, 2751 genes were included in the analysis.
Microarray data have been made available through the GEO data repository of the National Center for Biotechnology Information under series GSE2112.
Evaluation of differential expression between mouse models
Significance levels of differential gene expression differences between different classes of mouse models were calculated in R (38) using linear regression models that take the dye effect into account. All fixed-effects model were of this form:
In all comparisons, the expression levels of Cy3-labeled targets were captured in the intercept (dye=0), whereas dye equaled 1 for Cy5-labeled targets.
In the comparison of the different strains, the expression levels of C57Bl/10 were captured in the intercept (class=0), and different β coefficients were estimated for the other strains.
In the comparison of severely affected (mdx, mdx 3cv , Sgca null, Sgcb null, Sgcd null, Sgcg null) and non-or mildly affected (C57Bl/10, C57Bl/6, Sspn null, Dysf null, SJL Dysf ) models, the expression levels of non-or mildly affected were captured in the intercept (class=0), and class equaled 1 for severely affected mouse models.
Similary, in the comparison of dystrophin-deficient (mdx, mdx 3cv ) and sarcoglycan-deficient (Sgca null, Sgcb null, Sgcd null, Sgcg null) mouse models, expression levels of dystrophindeficient mice were captured in the intercept (class=0), and class equaled 1 for sarcoglycandeficient mice.
Similarly, in the comparison of dysferlin-deficient (Dysf null, SJL Dysf ) vs. control (C57Bl/10, C57Bl/6) mouse models, expression levels of control mice were captured in the intercept (class=0), and class equaled 1 for dysferlin-deficient mice.
P values for class were corrected for multiple testing using the method proposed by Benjamini and Hochberg (BH-correction) (39).
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To find biomarker genes for disease progression, we fitted the following models:
In model 2, we compared nonaffected (intercept; C57Bl/10, C57Bl/6, Sspn null) with mildly affected (class2=1; Dysf null, SJL Dysf ), and in model 3, we compared mildly affected (intercept; Dysf null, SJL Dysf ) with severely affected (class3=1; mdx, mdx 3cv , Sgca null, Sgcb null, Sgcd null, Sgcg null). We selected genes with significant P values (BH-corrected P value<0.05) in both comparisons and then identified up-regulated biomarker genes as genes with both β 2 and β 3 greater than zero, whereas for down-regulated biomarker genes both β 2 and β 3 were smaller than zero.
Clustering
Unsupervised hierarchical clustering was performed using the Functional Genomics package within Spotfire DecisionSite 7.3. Expression levels were scaled such that the average expression per gene over all conditions was zero. Average linkage was the clustering method applied, and Euclidean distance was taken as similarity measure.
Functional annotation
Recent functional annotation of genes was obtained from the SOURCE database (http://source.stanford.edu) (40). Genes were classified based on gene ontology using the webbased tool Gene Ontology Tree Machine (GOTM; http://genereg.ornl.gov/gotm) (41). Using this tool, we identified the functional processes that were overrepresented in lists of up-and downregulated genes compared with the list of all the genes on the array using a hypergeometric test. Only categories containing at least three differentially expressed genes and with a P value < 0.001 were considered.
Quantitative RT-PCR
Quantitative RT-PCR was performed as described previously (25). Gene expression levels were calculated using the gene expression macro provided by Bio-Rad (Bio-Rad, Hercules, CA) and normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH, stable expression in all samples) expression levels. Primer sequences are available on request.
RESULTS
We applied large-scale gene expression profiling to make a global inventory of differences in gene expression levels between mouse models for different muscular dystrophies. Nine mouse models with different genetic defects ( Table 1) and two wild-type mouse strains were compared. Total RNA, isolated from hindlimb muscle of two individual mice, was amplified and hybridized to murine microarrays containing 7445 gene-specific oligonucleotides, spotted in duplicate. A dye-balanced, randomized hybridization design was chosen to avoid potential dye, sample processing, and hybridization biases (Supplemental Table 1 ). Combined with an intensity-based analysis procedure, this experimental design is most efficient when comparing large numbers of groups (36).
After being filtered for unreliable spots and for genes the expression of which was known to be affected by differences in genetic backgrounds (34), 2171 genes demonstrated differential expression in the 11 models (P<0.05, BH-correction). These genes, as well as their expression levels in the different models, are listed in Supplemental Table 2 . We applied unsupervised hierarchical clustering on the profiles of the 300 most significantly differentially expressed genes to determine the similarity between the mouse models ( Fig. 2A) . According to the hierarchical clustering, two groups can be clearly discerned. The first group (I) contains the models for dystrophinopathy and sarcoglycanopathy, which have a severe dystrophic phenotype at the age of 8 wk. The second group (II) consists of models with a mild or unaffected phenotype.
The identity of the genes that contribute most to the distinction between group I and group II was determined by calculating per gene the statistical significance between the two groups with a linear regression model. After correction for multiple testing, 1028 genes appear to function as general markers for dystrophic muscles (Supplemental Table 3 ). In Table 2 , we present the genes that are at least twofold up-regulated or down-regulated (128 and 46 genes, respectively) in the mouse models for dystrophinopathy and sarcoglycanopathy, compared with mildly affected or unaffected muscle tissue.
To determine the biological variation in gene expression between the two individual mice from each strain, we performed a hierarchical clustering on the 300 most significant genes using the average gene expression levels of all separate individuals (Fig. 2B) . Within the group of mildly and nonaffected mouse models (group II), both individuals of each strain clustered together, demonstrating a high level of similarity in their gene expression profiles. In contrast, within the group of severely affected mouse models (group I), the gene expression profiles of the biological replicates were located in different clusters, which is indicative of a higher variability in gene expression profiles between individuals than between models.
To assess whether the absence of one DGC component affects the expression of other DGC components, we evaluated the expression levels of seven genes involved in the DGC (Dmd, Sgca, Sgcb, Sgcg, Sgcd, Sspn, and Dysf; Fig. 3) . The knockout mouse models demonstrated clearly reduced mRNA levels of the targeted gene, with an exception for Sgcd in Sgcd null mice and Dysf in dysferlin-deficient mice, in which both only a relatively modest decrease in signal intensity is shown. The effect of a point mutation (mdx, mdx 3cv , and SJL Dysf ) seems to have a milder influence on the mRNA levels, probably due to less efficient degradation by nonsensemediated mRNA decay (NMD), which depends on the location of the mutation (42, 43). In the mouse models for sarcoglycanopathy, a decrease in expression levels from other DGC components was observed, with largest effects in Sgca null mice. The gene expression of dysferlin, on the other hand, was up-regulated in severely dystrophic mouse models, with the exception of Sgcb null mice.
We implemented a recently published bioinformatics tool based on gene ontology (GOTM; ref 41) to investigate the functional processes active in severely affected dystrophic muscle tissue (group I). This tool associates sets of genes (e.g., up-regulated genes) with functional processes and determines whether these processes are represented at a higher frequency than can be expected by chance, i.e., as represented in the reference gene list, consisting of all genes on the microarray. The results of this analysis are presented in Fig. 4 . The most strikingly overrepresented biological processes in the list of up-regulated genes are cell adhesion (Icam1, P-selectin and several integrins, laminins, and thrombospondins), inflammation (many chemokines, cytokines, cytokine receptors, lymphocyte antigens), and regulation of muscle contraction (Atpa2, Calsequestrin 1 and 2, and Troponin C, I, T1, and T2). Many of the upregulated genes localized either in the extracellular matrix (including 12 different collagens) or in the lysosome. The most striking feature of the list of down-regulated genes is the participation of 53% of these genes (259 genes) in highly diverse metabolic processes, indicative of an overall decline in metabolic activity in dystrophic tissue. A large number of the gene products of these genes are localized in the mitochondrion (72 genes; P value for overrepresentation: 5.48×10
−24 ).
The individual genes in the listed functional categories are given in Supplemental Table 4 .
Although gene expression profiles of mouse models for dystrophinopathy show high similarity with those of mouse models for sarcoglycanopathy, some genes displayed statistically significant differential gene expression between these groups. With the linear regression model described in Materials and Methods, we found 46 differentially expressed genes (P<0.05 after BH-correction for multiple testing, Supplemental Table 5 ). A selection of four genes with greater than twofold lower expression and five genes with greater than twofold higher expression in mouse models with sarcoglycanopathy compared with mouse models for dystrophinopathy is presented in Table  3 .
The clustering diagrams in Fig. 2 suggest that gene expression patterns of mildly affected dysferlin-deficient animals can be discerned from those of healthy mice. With a linear regression model, 321 genes were identified that displayed statistically significant (P<0.05 after BHcorrection) differences in expression levels between dysferlin-deficient (SJL Dysf and Dysf null mice) and the two wild-type strains (Supplemental Table 6 ). Interestingly, the majority of upregulated (101/154) and down-regulated (88/167) genes were also differentially expressed between group I (severely affected) and group II (mildly or nonaffected). Since the latter group includes the dysferlin-deficient mice, these are genes with subtle changes in dysferlin-deficient mice and higher fold changes in the more severe models. We statistically evaluated which genes show a significant trend in expression level from nonaffected to mildly and to severely affected animal models. These genes can be seen as biomarker genes for disease severity. The heat map in Fig. 5 illustrates the expression levels of the 33 identified biomarker genes.
Two genes up-regulated in both mildly and severely affected animal models, S100a9, coding for a phagocytic protein known as calgranulin B, and Spp1, coding for a cytokine known as osteopontin, were also up-regulated in sarcospan-deficient mice (P<10 −7 after correction for multiple testing). This observation suggests for the first time a subtle molecular phenotype for these mice. With quantitative RT-PCR, we confirmed the much higher expression of Spp1 and S100a9 in sarcospan-deficient mice (29-and 14-fold increase over wild-types, respectively), as well as in the other muscular dystrophy models (Supplemental Fig. 1 ).
DISCUSSION
In this report, we have classified muscular dystrophies based on gene expression profiles in skeletal muscle of 8-wk-old mice. Cluster analysis readily distinguished severely affected mouse models (dystrophinopathies and sarcoglycanopathies) from dysferlin-and sarcospan-deficient and wild-type mice. Earlier studies demonstrated a high similarity in the histology of muscles from mouse models for dystrophinopathy and sarcoglycanopathies at the age of 8 wk (27-29, 32, 44, 45). We now show that common denominators in dystrophinopathies and sarcoglycanopathies are also apparent at the molecular level. The robustness of this classification is further illustrated by the fact that one of the two mouse models for β-sarcoglycan deficiency (29, 30) that were originally included in the study, clustered with the non-or mildly affected mice. Since this was highly unexpected, a detailed analysis was performed using histological techniques and RT-PCR, showing that one of the two mice analyzed was incorrectly genotyped as a Sgcb null mouse instead of wild-type. As a consequence, we had to exclude the second Sgcb null model from further analysis.
Gene expression levels of DGC components decrease in DGC-related muscular dystrophies
Although the entire DGC is absent from the sarcolemma in dystrophinopathies, whereas only the SGC is lost in sarcoglycanopathies, we observed a general decrease in mRNA levels of the DGC components in both dystrophin-and sarcoglycan-deficient mice. The instability of the DGC apparently triggers a negative feedback to transcriptional levels of the DGC components. Notable is the up-regulation of dysferlin, which is indicative for an increased need for membrane repair systems to prevent membrane leaking or rupture, a common feature for muscular dystrophies (46, 47) . Other important processes secondary to the genetic defect and the loss of a functional DGC are induction of an immune response, increased expression of cellular adhesion and extracellular matrix proteins, and changes in cytoskeletal organization. These processes were also shared between human patients with DMD and LGMD-2D (α-sarcoglycan deficiency) (16) .
The inflammatory response in muscular dystrophy can be divided into multiple components
By looking at markers for different types of immune cells (48), we found evidence for the infiltration and accumulation of macrophages [Cd68, Lgals3 (Mac-2), Mpeg1, Clecsf12], B-cells (Cd83, Blnk), T-cells (CD8b1, Ly6e), and NK-cells (Ypel1). The recruitment of inflammatory cells is probably mediated by CC-class chemokines that are up-regulated (Ccl2, Ccl6, Ccl7, Ccl8, and Ccl9), as was reported for mdx mice (25, 49, 50) . Furthermore, an activation of components of the complement system (C1qa, C1qg, C1qr1, C1qTNF3, and C3ar1) was observed, which contributes to the inflammatory response in dystrophic muscle by further damaging cell membranes and releasing complement split products that attract macrophages for phagocytosis.
Genes involved in sarcomeric organization and extracellular matrix formation are upregulated in both sarcoglycan-and dystrophin-deficient muscles
Among the up-regulated extracellular matrix proteins are 12 different collagens, laminin α4, B1 and gamma1, and collagen binding proteins such as biglycan. The up-regulated cytoskeletal proteins include the intermediate filament vimentin, the microtubular components tubulin α-1, -2, -6, and β-5, the actin-interacting protein transgelin2 and the sarcomeric troponins I (skeletal, slow), T1 (skeletal, slow), T2 (cardiac), C (cardiac / slow skeletal), most of which having been reported before as up-regulated in mdx mice (25, 50-52). Such up-regulation of extracellular and intracellular structural proteins, which is also found in human DMD patients (17) (18) (19) 53 ) might compensate for the loss of force-generating capacity due to the instability of the DGC-mediated link between the cytoskeleton and the extracellular matrix.
Dystrophic muscle tissue experiences a metabolic crisis
The large number of down-regulated genes functioning in diverse metabolic processes reflects probably the metabolic crisis also seen in human DMD, LGMD-2D, FSHD, and nemaline myopathy patients (16, 22, 23) . From our and data of others (51, 52), we conclude that the metabolic crisis in mdx mice is less severe than in sarcoglycan-deficient mice. However, a reduction in the respiratory rate of mitochondria in skeletal muscle of both mdx mice and DMD patients was also found in previous studies using other techniques (54, 55) .
Differential gene expression between dystrophinopathies and sarcoglycanopathies
Despite the high similarities between dystrophinopathies and sarcoglycanopathies at 8 wk of age, 46 genes were found significantly differentially expressed between these groups. This may indicate that there are some subtle differences between dystrophinopathies and sarcoglycanopathies. These differences may become more prominent at higher age, since the mdx mice, in contrast to the sarcoglycan-deficient animals, make an almost complete recovery. A more extensive temporal gene expression profiling study together with functional analysis of the identified proteins is necessary to characterize the differences (work in progress). Cysteine and glycine-rich protein 3 (Csrp3), a positive regulator myogenesis (56), was the most prominent, higher expressed gene in sarcoglycan-deficient compared with dystrophin-deficient animals. Interestingly, it has been found before that Csrp3 is also up-regulated in human FSHD but not DMD patients (22). This exemplifies that muscular dystrophies share some aberrations in gene expression and differ in others, and that it would be feasible to find a specific disease signature based on the measurement of the expression of combinations of genes.
Vascular irregularities are not likely to contribute to muscular dystrophy
Mutations in smooth muscle SGC-components (Sgcb, Sgcg, Sgcd) lead to vascular irregularities, which are thought to exacerbate the cardiac pathology seen in mice deficient for the individual components (29, 57, 58). Alpha-sarcoglycan is not expressed in smooth muscle and therefore the Sgca null mouse does not have altered SGC expression in smooth muscle. We show that the gene expression profiles of Sgca null mice are highly similar to the gene expression profiles of the other sarcoglycan-deficient mouse models, corroborating the suggestion of Durbeej et al. that vascular irregularities are not likely to contribute to the skeletal muscle pathology (24).
Differential gene expression precedes histological changes in dysferlinopathies
The phenotype of dysferlin-deficient mice is less progressive than that of the dystrophin-and sarcoglycan-deficient mice (11, 26) . HE staining shows only few necrotic fibers at the age of 8 wk, corresponding with the higher age of onset of dysferlinopathies, both in mice and humans. Still, we observe significant differences in gene expression between wild-type mice and dysferlin-deficient mice at the age of 8 wk. Among the up-regulated genes that have also been found in an earlier study in SJL mice (13) are: Troponins T1, C, and I, Ccl2, Cd53, Cd68, Cd83, P lysozyme structural, tissue inhibitor of metalloproteinase 1 and 4. Many of these genes (Fig. 5) are more severely changed in the severely affected mouse models. Thus, in dysferlin-deficient mice, similar to dystrophin and sarcoglycan-deficient mice, inflammatory and muscle remodeling processes play an important role (confirmed by gene ontology analysis with GOTM, not shown). Although differences in the expression of these genes are still limited at the age of 8 wk, they may become more prominent at higher ages. In the mdx mouse, however, the expression of these genes is already increased at 4 wk and peaks at 6 wk (25), in agreement with the earlier age of onset in dystrophinopathies. Consequently, these genes can be regarded as markers for disease progression.
A molecular phenotype for sarcospan-deficient mice
Genes, coding for secreted phosphoprotein 1 (Spp1 or Osteopontin), functioning in chemotaxis, and the phagocytic S100 calcium binding protein A9 (S100a9 or Calgranulin B), are also upregulated in sarcospan-deficient mice. Differential expression of these genes indicates that sarcospan-deficiency may induce a subtle immune response in muscle. Spp1 seems to be an extremely sensitive marker for muscle pathology, since it was picked up in other gene expression profiling studies in dystrophin-deficient humans and mice (18, 51) .
Inter-individual variation in gene expression levels
Our study shows that the inter-individual differences in expression levels are considerable, even in genetically identical mice. Consequently, the subtle differences that discriminate between the muscular dystrophies will only become significant when large sample groups are analyzed. We suppose that the inter-individual differences in the severely affected mice are related to the physical behavior or the amount of exercise. An increase in muscle activity leads to an increase in sarcolemmal rupture, which initiates the secondary processes responsible for the severity of the disease (59, 60). Recently observed inter-individual variability in satellite cell number (61) and possibly regenerative potential in dystrophic mice, may also contribute to the observed variability. Due to the interindividual variability, at least 4 animals per group were required for meaningful comparisons. This is why classes of genotypes were combined in the performed statistical tests (e.g., the class of dysferlin-deficient mice, consisting of the 2 SJL Dysf and 2 dysferlin null individuals). In humans, many more genetic and environmental factors will contribute to the inter-individual variation (62), and building of a robust classifier necessary for muscular gene expression profiling-based diagnosis of muscular dystrophies would necessitate the analysis a large number of samples per group. On the other hand, analysis of disease progression using the biomarker set described here, would be more readily achievable, although more definitive correlations between expression levels of the identified biomarkers and other pathological parameters need to be established. This type of analysis would be useful to monitor response to treatment.
CONCLUSION
In summary, we have found remarkable similarity in the expression patterns of dystrophin-, sarcoglycan-, and dysferlin-deficient mice. Genes functioning in the inflammatory response and structural organization are significantly up-regulated compared with wild-type mice, whereas metabolism genes are down-regulated. We conclude that common pathogenic mechanisms underlay the onset and progression of different forms of muscular dystrophy in mice. Given the similarity with published human studies on specific forms of muscular dystrophy, these pathogenic mechanisms may also contribute to the different forms of muscular dystrophy in humans. Furthermore, we have identified sets of biomarker genes that can be used to monitor disease progression in muscular dystrophies, thereby taking the first step toward the development of a diagnostic approach for muscular dystrophies by expression profiling-based classification. clustering was performed on averaged expression levels of each strain for 300 genes that display most significant (BHcorrected P value < 4.5×10 −8 ) differences in expression between strains. For better visualization of up-and downregulation, gene expression levels were scaled to an average value of 0. Euclidean distance was used as a distance measure. Based on clustering, 2 major groups can be discerned (I and II). B) Unsupervised hierarchical clustering was performed on averaged normalized gene expression levels per individual of 300 genes that display most significant (BH-corrected P value < 4.1×10 −5 ) differences in expression between severely affected and non-or mildly affected animal models. The clustering and visualization method applied was identical to that in A.
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